Coverage in The Australian

Interesting commentary by Rebecca Urban in The Australian this morning. A big thank you to the hundreds of people from the Australian biosciences industry who reached out in personal support over the past few weeks. I actually wish Chris Roberts every success. Notwithstanding my views on the product, if anyone should be able to fix the company’s corporate governance,…

[Site Policy] 16/01/2016 : Publication of Legal Intimidation

Received 16/01/206 from Kim Hogan, Forrest Capital (iPhone screen snapshot). This information is published per site policy. Notes: Electronic harassment is an important focus area of law reform in Australia. Australian state and territory criminal laws criminalise harassment through electronic communication, although offences vary considerably depending on the jurisdiction. For example, in Victoria, the definition of stalking extends to a…

OSL : Follow-up

Since my last post on OSL (ASX : OSL), I’ve had a few interesting reach-outs confirming my viewpoint on this company and also providing a bit more “colour”. I should note that all of this information is actually reasonably consistent with the discussion I had with Daniel Kenny (CEO) last week, with one exception and I…

Imugene’s Monster Raise

Following last week’s ASX trading halt request, I have been waiting for the announcement regarding Imugene’s (ASX : IMU) financing. The news came at market open this morning, specifically that the company had placed $3m through the “usual suspects”. Combined with the end-year disclosure, this means the company has about $5m in the bank +/- 10% with a…

The Next Great ASX Biotech?

Every once in a while I read a news item that leaves me in a state of semi-shock and, let’s face it, that is a pretty high bar given the messed-up world we live in. This weekend, I spent a bit of time catching up on current affairs (as one does on a lazy Sunday morning) and…

Cynata Therapeutics : The Flip Flop

I make no effort to hide the fact that Cynata (ASX : CYP) is one of the ASX-listed biotechnology companies that I despise the most. It is the worst example of a “hollow chocolate bunny” that will only ever deliver on wild speculation from retail punters wowed by the words “stem cells.” If, one day,…

Actinogen : Another Martin Rogers “Special”

I spent much of the weekend thinking about this post and exactly what I would say about Actinogen (ASX : ACW). It’s a tough one because the things I really want to say don’t have a linguistic composition suitable for a G-rated public forum. But I will do my best to exercise restraint… Let’s start by looking back…